STOCKHOLM – May 3, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announces that Kerstin Hasselgren has been appointed CFO of the company. Kerstin has extensive experience from working in publicly listed international companies, including positions as Vice President Finance at AstraZeneca within Global R&D and Global Operations. Most recently, Kerstin comes from a position as Vice President Business Control at SSAB. She is a graduate economist from Stockholm School of Economics.
“Xspray has grown considerably in the past year and the timing is now right to strengthen the organization with a CFO. Kerstin’s experience from listed international large companies will be very valuable in different areas, from the planned up-listing to Nasdaq Stockholm’s main list to partnership discussions with other global pharmaceutical companies,” says Per Andersson, CEO of Xspray Pharma.
“I really look forward to start working at Xspray. The company has a tremendously exciting business concept and product portfolio and is in a phase where I hope that my broad international experience and knowledge from the pharmaceutical industry can contribute to the company’s continued success,” says Kerstin Hasselgren.
Kerstin will take up her post by May 15, 2019 and will be part of Xspray’s management team.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB
Mobile: +46 (0) 706 88 23 4
The information was submitted for publication, through the agency of the contact person set out above, at 4.30 p.m. CET on 3 May 2019.
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered 39 in 2018. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.
The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Stockholm.
Redeye AB is Xspray Pharma’s Certified Adviser
+46 (0)8 121 576 90